| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Apixaban |
| Brand | Eliquis® |
| Indication | For the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery. |
| Assessment Process | |
| Rapid review commissioned | 19/10/2021 |
| Rapid review completed | 02/11/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 01/02/2012 |
| NCPE assessment completed | 19/06/2012 |
| NCPE assessment outcome | The NCPE believe that apixaban is cost effective for the prevention of VTE following total hip replacement and total knee replacement. |
